News Breaks |
|
|
| September 27, 2012 |
| 10:45 EDT |  | BAYRY, ONXX | FDA approves Stivarga for treatment of colorectal cancer
The FDA announced that it approved Stivarga to treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body. Stivarga is a multi-kinase inhibitor that blocks several enzymes that promote cancer growth. Stivarga is being approved one month ahead of the product’s prescription drug user fee goal date of Oct. 27, the date the agency was scheduled to complete review of the drug application. Stivarga is being approved with a Boxed Warning alerting patients and health care professionals that severe and fatal liver toxicity occurred in patients treated with Stivarga during clinical studies. Stivarga is marketed by Onyx Pharmaceuticals (ONXX) and Bayer (BAYRY). |
|
|
News For ONXX;BAYRY From The Last 14 Days Check below for free stories on ONXX;BAYRY the last two weeks. |
|
|
| May 17, 2013 |
| 06:33 EDT |  | BAYRY | American Thoracic Society to hold a conference
 Subscribe for More Information |
|
| May 15, 2013 |
| 11:43 EDT | | BAYRY | Bayer announces FDA approval for Xofigo as CRPC treatment
Subscribe for More Information |
|
| May 8, 2013 |
| 08:52 EDT |  | ONXX | Onyx Pharmaceuticals price target raised to $115 from $105 at Maxim
Subscribe for More Information |
|
| May 7, 2013 |
| 17:25 EDT | | BAYRY | Bayer commences cash tender offer for Conceptus shares
Subscribe for More Information |
|
| 16:01 EDT |  | ONXX | Onyx Pharmaceuticals reports Q1 EPS (47c), consensus (47c)
Reports Q1 revenue $145.5M, consensus $134.36M. |
|
| May 6, 2013 |
| 07:18 EDT | | BAYRY | American Congress of Obstetrics and Gynecology to hold annual meeting
Subscribe for More Information |
|
|
|
|
|
